Corbus Pharmaceuticals Holdings, Inc. updates its risk factors, stating its dependence on third parties for manufacturing its drug candidates and the potential impact on commercialization if those third parties fail to obtain manufacturing approval or provide sufficient quantities at acceptable quality levels or prices.